Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...
Altimmune Inc (NASDAQ:ALT) shares jumped 8.5% to $5.61 on Friday, ahead of next week’s presentation at the European Association for the Study of the Liver International Liver Congress 2025. The stock ...
GAITHERSBURG, Md., June 05, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflammatory and ...
LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...
Health and Me on MSN
Breaking 8 fatty liver myths that are ignored easily
Fatty liver disease is becoming increasingly common, yet many people still misunderstand what causes it and who is at risk. Because the condition often develops silently, it is easy to ignore early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results